$LWLG (Industry related) copy F2
Netflix urged to slow
$LWLG (Industry related) copy F2
Netflix urged to slow streaming to stop the internet from breaking
From CNN’s Hadas Gold
Shutterstock
Shutterstock
The European Union is urging Netflix and other streaming platforms to stop showing video in high definition to prevent the internet from breaking because of the coronavirus pandemic.
With so many countries on lockdowns to fight the spread of the virus, hundreds of millions working from home and even more children out of school, EU officials are concerned about the strain on internet bandwidth.
European Commissioner Thierry Breton tweeted Wednesday evening that he had spoken with Netflix CEO Reed Hastings. Breton called on viewers and companies to "#SwitchtoStandard definition when HD is not necessary" to secure internet access for all.
A Netflix spokesperson told CNN Business that Hastings and Breton will speak again on Thursday, and said it already adjusts streaming quality and tries to minimize bandwidth consumption.
"Commissioner Breton is right to highlight the importance of ensuring that the internet continues to run smoothly during this critical time," the Netflix spokesperson said. "We've been focused on network efficiency for many years, including providing our open connect service for free to telecommunications companies."
Facebook on Wednesday acknowledged that the effects of the pandemic were stretching it to the limit. In a call with reporters, CEO Mark Zuckerberg said Facebook was facing "big surges" in use as the coronavirus forces millions to stay home.
He described the increase in demand as "well beyond" the annual spike usually seen on New Year's Eve. Voice and video calls on WhatsApp and Facebook Messenger, in particular, are more than double usual levels.
A thought. Just saw the news that Netflix is urging users ‘to slow’ down so the internet doesn’t break. Article just out below... my kids both are locked into non stop use now of Zoom for education. The world faces a critical juncture for the need of something to be done in this arena.
It would be nice to hear a real update or see our first deal (better). All signs point to the internet at desperate capacity issues right now.
Please Dr. Lebby speak to us in light of what’s going on. I don’t think we can just wait for 6 more months of testing/tweaking.
One commercial validation would send this soaring and would make it so much easier better to capitalize.
F2
Lightwave Logic Inc (LWLG) Stock Research Links
$MJ
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...
Continue Reading
LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...
Continue Reading
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...
Continue Reading
Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...
Continue Reading
Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...
Continue Reading
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...
Continue Reading
Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...
Continue Reading
Top 5 Most Recently Viewed Articles
Morgan Stanley's Positive Outlook for Consumer Finance Stocks Morgan Stanley has recently made an uplifting adjustment to its outlook on consumer finance stocks, now branding them as "attractive." This decision stems from robust fundamentals and an improved regulatory environment, setting an optimistic tone for the sector. Key Drivers of Change The primary catalysts...
Continue Reading
O2Gold Board Announces Key Changes O2Gold Inc. (NEX: OTGO.H), a dedicated mineral exploration company, has recently undergone a significant change in its board structure. The company has announced that Roger Lemaitre has resigned from his position as a director. This decision marks a pivotal moment for O2Gold as it continues to navigate its exploration initiatives....
Continue Reading
Help for Homeowners During the Holidays In a time when financial strain can be prominent, especially during the holidays, Taylor Morrison (NYSE: TMHC) is stepping up to lend a hand. The renowned homebuilder has introduced an initiative designed to support homeowners facing the threat of foreclosure. With the holiday season often heightening financial challenges, the...
Continue Reading
flatexDEGIRO Ends Special Commissioner Mandate FRANKFURT - flatexDEGIRO AG, a prominent German financial services provider, has officially announced the conclusion of the special commissioner mandate set by the Federal Financial Supervisory Authority (BaFin). This change will take effect on a specified date in the future. The company has made significant strides in...
Continue Reading
Alvotech Faces Scrutiny over Manufacturing Issues National shareholder rights firm Hagens Berman is currently analyzing Alvotech (NASDAQ: ALVO) regarding potential misrepresentations in their disclosures tied to manufacturing operations and the regulatory status of their primary biosimilar candidate, AVT05. Impact of FDA's Complete Response Letter The investigation stems...
Continue Reading